CLU and cancer: The shift in CLU+/SMA+ CAF ratios in human patients, and the shift in Clu vs. Acta2 expression in PSCs conditioned by Brca2-deficient cancer cells, suggest that CAFs of BRCA-mutated tumors may undergo a shift from myofibroblastic to immune-regulatory functions.